Highlights Sarepta Therapeutics, Inc. Sao Paulo

Equities

Market Closed - Sao Paulo Other stock markets 01:09:40 27/06/2024 am IST			5-day change	1st Jan Change
43.08 ^BRL	-0.05%		+33.09%	+87.63%

26/06	Monetary policy is getting even more confusing
26/06	Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172	MT

Health Care Stocks Boosted By Duchenne MS Drug -- Health Care Roundup	22/06	DJ
Sector Update: Health Care Stocks Gain in Late Afternoon	22/06	MT
S&P, Nasdaq edge down as Nvidia declines for second day	22/06	RE
Top Midday Gainers	21/06	MT
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06	MT
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says	21/06	MT
S&P 500, Nasdaq lower as semiconductor shares weigh	21/06	RE
Sarepta surges as investors cheer expanded use of gene therapy	21/06	RE
Sector Update: Health Care Stocks Steady Premarket Friday	21/06	MT
Sector Update: Health Care	21/06	MT
Wavering Tech Rally Pushes Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday	21/06	MT
Top Premarket Gainers	21/06	MT
Sarepta surges as investors cheer expanded use of gene therapy	21/06	RE
Futures Down Pre-Bell as Traders Wait for Market Direction Cues; Asia, Europe Fall	21/06	MT
Wall Street futures edge lower ahead of business survey data	21/06	RE
Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy	21/06	MT
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket	21/06	MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours	21/06	MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump	21/06	RE
US FDA allows expanded use of Sarepta's Duchenne gene therapy	21/06	RE

No results for this search